Project Grant R15AG091199
Award Date
12/15/24
Completion Date
11/30/27
Dollars Obligated
$372K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Fort Lauderdale, FL 33328, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $720,621 to the University of Massachusetts Medical School to investigate the role of peripheral insulin resistance and inflammation in Alzheimer's disease (AD) pathogenesis. The key objectives are to:
Define age-related changes in metabolism and inflammation in peripheral organs and the brain during AD-relevant neurodegeneration in a mouse model. This includes measuring organ-specific...
This $3,357,206 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports the development of a novel disease-modifying compound, BMS-984923, to treat Alzheimer's disease (AD). The grant recipient, Allyx Therapeutics Inc., will conduct clinical evaluation of BMS-984923 to evaluate its efficacy in restoring synapse density, hippocampal activity, and memory performance in preclinical AD models. The ultimate goal is to advance this small molecule...
The National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), awarded a $500,000 Project Grant to Alzarrok Bio LLC for the development of a multi-target peptide drug for Alzheimer's disease (AD). The proposed peptide, named ALZ100, is derived from the human defense protein cathepsin G and is designed to inhibit four key mediators of AD pathogenesis: amyloid-beta (Aβ) oligomers and fibrils, the receptor for advanced glycation end-products (RAGE), the...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides funding to Florida International University (FIU) to conduct research on the effects of a small molecule activator of autophagy, called TPI-132, on insulin signaling, senescence, and neuropathology in mouse models of Alzheimer's disease. The total award amount is $479,375 with a performance period from December 1, 2024 to November 30, 2026. The key objectives are to optimize the...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development of a high-content screening pipeline to identify small molecule therapeutics that can reduce aberrant lipid accumulation in ApoE4-expressing oligodendrocytes, a key pathological feature of Alzheimer's disease. The $473,216 award, effective September 25, 2024 through August 31, 2025, will support two aims: (1) a targeted screen of ~2,500 lipid-modifying compounds and (2) an...
This $249,000 project grant, awarded by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), aims to investigate the mechanisms by which midlife obesity and prediabetes contribute to later-life cognitive decline and Alzheimer's disease-related dementias (AD/ADRD). The key objectives are to:
Establish the role of the cGAS/STING inflammatory pathway and the broader inflammatory milieu during the progression from midlife obesity and prediabetes to later-life...
This $2,085,904 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to investigate the role of glycated tau and advanced glycation end products (AGEs) in the pathology, neurotoxicity, aggregation, and neuroinflammation associated with Alzheimer's disease (AD). The 5-year project, commencing on May 1, 2024, will be conducted by the University of Colorado and aims to provide molecular-level insights into the connections between type 2...
This federal Project Grant award (R03AG087475) for $295,000 from the National Institute on Aging (NIA) under the Aging Research (CFDA 93.866) program aims to develop biotherapeutic nanogels for the treatment of Alzheimer's disease (AD). The project utilizes patented autofluorescent biopolymeric nanogels with anti-viral properties, biodegradability, and cellular biocompatibility to target key AD biomarkers, including amyloid-beta, neurofibrillary tangles, and inflammatory markers. The goals...
This federal Project Grant award for $218,261, provided by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), aims to advance the understanding of the molecular connection between obesity and Alzheimer's disease (AD). The principal investigator (PI) at the University of Virginia (UVA) will conduct a two-year exploratory study to:
Genetically identify the molecular pathways through which obesity activates the MOAG-4 protein in neuronal cells of the model...
This federal Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), provides $499,883 to Degrome Therapeutics, Inc. to develop small-molecule degraders of amyloid precursor protein (APP) as novel therapies for Alzheimer's disease (AD). The goal is to identify lead compounds that can effectively degrade APP, thereby reducing amyloid-beta (Aβ) production and accumulation, which plays a key role in AD pathogenesis. The project will involve...